Summary. Endothelin-like immunoreactivity (ET-IR) was detected immunocytochemically in glandular epithelium and vascular endothelium of human endometrium and myometrium. Primary antibody was raised in rabbits against the carboxy-terminal heptapeptide of endothelin 1 (ET-1), ET-1(15\p=n-\21),and compared with antibodies raised against the cyclized amino-terminal, ET-1(2\p=n-\13),and commercially obtained antibodies against the whole ET-1 or ET-3 molecule. Binding was visualized using the peroxidase technique in sections counter-stained with haemalum. Staining was seen in each of 15 sections from eight women in the proliferative (five) or secretory (three) phase of the cycle. Intense staining was present in the cytoplasm of endometrial glands and vascular endothelium, and was greatest at the endometrial\p=n-\myometrialjunction. The pattern of staining was similar with all primary antibodies tested. The demonstration of ET-IR in endometrium suggests that the endothelins may play a role in control of the uterine vascular bed.
Introduction
The production of a powerful vasoconstrictor in basal endometrium plays a crucial part in the mechanism of menstruation. Intense vasoconstriction of the endometrial spiral arterioles occurs immediately before the onset of menses (Markee, 1940) . Furthermore, most of the functioning endometrium is shed within the first 20-24 h of menstruation, and subsequent haemostasis is achieved not by the deposition of platelet-fibrin plugs (Wester et al, 1978) , but by vasoconstriction of the remaining basal arteriolar fragments (Christiaens et al, 1980) . The best candidate for the endometrial vasoconstrictor has been prostaglandin F2a, but it is a weak pressor agent, and in vitro studies failed to demonstrate significant vasoconstrictor activity on small uterine arterioles (Maigaard et al, 1985) .
The endothelins are potent vasoactive agents (Yanagisawa et al, 1988) . Genomic sequencing has predicted three distinct isopeptides, ET-1, (Inoue et al, 1989) . In addition to its powerful vasoconstrictor actions, ET-1 stimulates the release of prostanoids and endotheliumderived relaxing factor (DeNucci et al, 1988) , and is co-mitogenic for vascular smooth muscle cells. The release of immunoreactive ET-1 has recently been described from rabbit endometrial cells in primary culture (Orlando et al, 1990) . We have demonstrated the presence of specific binding sites for iodinated ET-1, ET-2 and ET-3 in human uterus (Davenport et al, 1991) ; this study reports the localization of ET-like immunoreactivity in endometrium and myometrium using immunocytochemistry. 
Antisera
Primary antibodies were raised in rabbits to the carboxy-terminal heptapeptide of ET-1, ET-1(15_21), synthesized using solid phase tertiary butoxycarbonyl (t-BOC) chemistry. The identity of the peptide was confirmed by amino acid sequencing before conjugation to purified protein derivative of tuberculin using sulfosuccinimidyl 4-(yV-maleimidomethyl) cyclohexane-1-carboxylate. For comparison, antibodies that had been raised in rabbits to the cyclized aminoterminal, ET-1(2 _ 13, were used. Commercial rabbit polyclonal antibodies against whole ET-1 (Peninsula RAS 6901-N, which crossreacts with ET-1 (100%), human ET-1 (17%), ET-2 (< 10%) and ET-3 ( < 10%)) or ET-3 (Peninsula RAS 691I-N, which crossreacts with ET-3 (100%), ET-2 (<1%) and ET-1 (<2%)) were also evaluated. Solid phase immunoabsorbent assay (ELISA), and radioimmunoassay, confirmed that antibodies recognized unlabelled and iodinated ET peptides respectively.
Evaluation of antisera
Positive controls included the detection of staining in the cytoplasm of human umbilical artery and vein endothelial cells. No staining was seen when primary antibody was omitted or pre-immune sera substituted. Controls were also performed by pre-absorbing antibodies with synthetic ET peptides (10~6mol 1) for 48 h to abolish stain¬ ing. Specificity of the antisera was determined by incubating primary antibodies with peptides unrelated to the endothelins, which may be present in uterine tissues, or which have a similar cyclic structure, used at 10"6 mol I"1; CGRP, ANF, VIP (human), CCK-4, pentagastrin, somatostatin, substance P, eledoisin, dynorphin A(l-6), YGGFMR, (Met5)-enkephalin, bradykinin, neuropeptide Y and EGF.
No staining was detected in negative control sections in which primary antibody had been omitted, or pre-immune rabbit sera substituted at the same concentration as primary antibody.
Immunocytochemistry
Tissue was collected from eight women undergoing hysterectomy for benign disease. Informed consent was obtained, and the study was approved by the Cambridge Health Authority District Ethical Committee. Samples were immediately snap-frozen in liquid nitrogen, and stored at -80°C until processed.
Thick cryostat sections, 30 pm, (15 from each patient), taken through the whole thickness of endometrium and adjacent myometrium, were thaw-mounted onto gelatin-subbed slides and allowed to warm to room temperature. The sections were fixed in 4% formaldehyde, and incubated with 10% goat serum to block nonspecific staining. Sections were then incubated with primary antibody for 60 h at a dilution of 1:300 (v/v), and tested over the range 1:100 to 1:1000. Binding was visualized using an anti-rabbit second antibody (diluted 1:200, (v/v) in 005 mol phosphate-buffered saline l-1, pH 7-4) followed by rabbit peroxidase-anti-peroxidase (1:400, v/v). The complex was detected with diaminobenzidine and hydrogen peroxide in 005 mol Tris HCl 1_1 (pH 7-4) in sections counterstained with haemalum (Sternberger et ai, 1970) .
Results
Five specimens were in the proliferative phase (days 2, 6, 7, 13, 14) and three in the secretory phase (days 15, 20, 23) , based on the date of the last menstrual period, and confirmed by histological assessment.
Endothelin-like immunoreactivity was detected in all tissues examined, and with each antibody, over the concentration range 1:100 to 1:1000. Although the pattern of staining with the carboxyterminus antibody, ET-1(15_21) was similar to all other antibodies tested, the intensity of staining was lower with both ET-1(2_13), and the commercial antibody RAS 6901-N, tested at the same dilution, and processed in the same assay (Figs 1 and 2) . A reduced intensity of staining was also seen with the antibody raised against (RAS 6911-N) . Staining was localized to the cytoplasm of endometrial glandular epithelium, and was most intense, both in terms of the density of the reaction product, and the number of glandular cells stained, at the endometrial-myometrial junc¬ tion (Fig. la, d ). All gland cells were stained in secretory tissue (Fig. le) (Fig. 2a) . No staining was seen in vascular smooth muscle cells or myometrium. Staining was not affected by pre-absorption with non-ET peptides, but was abolished after pre-absorption of the ET-1(15_21) antibody with ET-1, ET-2 and ET-3. Staining was not affected by pre-absorbing ET-1(2_13) antisera with ET-3. (Orlando et al, 1990) , supporting an involvement in the paracrine control of myometrial contractions (Bousso-Mittler et al, 1989) , and subsequent work has demonstrated ET-IR on endometrial surface epithelium in immature rabbits, with localization to endometrial stroma after steroid priming (Maggi et al, 1991) . In the present study, the pattern of staining in human endometrium was similar to that of autoradiographically localized binding sites for iodinated ET-1, ET-2 and ET-3, concentrated around basal endometrial glands (Davenport et al, 1991) . Intense vasoconstriction in the basal endometrium appears to play a crucial role in the mechanism of menstruation (Markee, 1940; Christiaens et al, 1980) . The demonstration of both ET-IR and specific binding of iodinated peptide concentrated at the endometrial-myometrial junction might offer an alternative to PGF2a as the endometrial vasoconstrictor. The immunocytochemical localization of ET-IR in basal endometrium suggests that these potent peptides may not only be candidates for the endometrial vasoconstrictor, but may also be involved in the mediation of uterine contractions, endometrial proliferation and implantation.
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